Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Codagenix Inc.

http://www.codagenix.com

Latest From Codagenix Inc.

Codagenix Eyes '23 Nasal RSV Vaccine Readout As GSK, Pfizer Set To Establish Lead

Codagenix hopes a 2023 data readout from its intranasal RSV vaccine will be an inflection point, even as GSK and Pfizer look to establish a lead in the segment. Meanwhile, a second cancer candidate has been added to Codagenix's preclinical pipeline and data for its COVID-19 vaccine and TNBC oncolytic virus are expected next year, CEO Robert Coleman tells Scrip.

Vaccines Leadership

Next-Gen COVID Vaccines Could Be Awesome – If They Ever Get Made

Mucosal and other new vaccines in development should target infection and transmission prevention, as White House’s Ashish Jha calls for them to be ‘better than terrific.’ But with the market transitioning to a flu-like status, incentives for big investments seem limited.

Coronavirus COVID-19 Vaccines

More Candidate COVID-19 Vaccines Expected To Enter WHO’s Global Trial

A new global clinical trial initiative is assessing a number of second-generation candidate vaccines for COVID-19. The Australian medicines regulator has given the go-ahead for an approval application for one of the vaccines, from Taiwan’s Medigen.

Coronavirus COVID-19 Vaccines

Deal Watch: Visus Begins Charting Its Direction In Ophthalmology With Two Deals

Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
UsernamePublicRestriction

Register